title: First-in-class anemia drug takes aim at Amgen's dominion.
authors.forename: Aaron
authors.initials: A
authors.lastname: Bouchie
mesh_terms: D000740:Anemia / Q000150:complications / Q000188:drug therapy*; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases / Q000037:antagonists & inhibitors; D007546:Isoquinolines / Q000494:pharmacology / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000097:blood*
chemical_list: D007546:Isoquinolines; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D005998:Glycine; C584543:roxadustat